• Users Online: 1170
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 2  |  Issue : 2  |  Page : 500-502

A case of multifocal uveal metastases from T790M-mutated non-small-cell lung carcinoma with an unexpected reaction to Osimertinib


Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin Province, China

Correspondence Address:
Wen-Song Zhang
Department of Ophthalmology, The Second Hospital of Jilin University, Yatai Street, Changchun - 130 000, Jilin Province
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_2061_21

Rights and Permissions

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of metastatic non-small-cell lung carcinoma (NSCLC) patients with targetable EGFR-T790M mutations. We describe the case of a 61-year-old Chinese female confirmed with multifocal uveal metastases from T790M-mutated NSCLC after developing acquired resistance to icotinib (a first-generation EGFR-TKI). Therefore, she was instituted on oral osimertinib. The uveal masses were reported to completely disappear on anterior segment examination, ultrasound biomicroscopy (UBM), and ocular color doppler flow imaging (CDFI) after 41 weeks. However, the patient got worse and eventually died from systemic metastases 4 months later.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed98    
    Printed0    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal